Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander E Perl

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Archives of Pathology & Laboratory Medicine|September 2, 2025
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With QuizartinibJaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk StratificationCheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, et al.
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Leukemia & Lymphoma|June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementationCraig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemiaMolly E Graveno, Alison Carulli, Craig W Freyer, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Cancer Cell|February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutaratePatrick S Ward, Jay Patel, David R Wise, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Archives of Pathology & Laboratory Medicine|September 2, 2025
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With QuizartinibJaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk StratificationCheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, et al.
Blood Cancer Journal|May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenibAlexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Leukemia & Lymphoma|June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementationCraig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemiaMolly E Graveno, Alison Carulli, Craig W Freyer, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Cancer Cell|February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutaratePatrick S Ward, Jay Patel, David R Wise, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Pageof 9